|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLYWCH2 |
Gene summary for FLYWCH2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLYWCH2 | Gene ID | 114984 |
| Gene name | FLYWCH family member 2 | |
| Gene Alias | FLYWCH2 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q96CP2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114984 | FLYWCH2 | LZE2T | Human | Esophagus | ESCC | 9.02e-07 | 6.39e-01 | 0.082 |
| 114984 | FLYWCH2 | LZE4T | Human | Esophagus | ESCC | 1.00e-18 | 4.64e-01 | 0.0811 |
| 114984 | FLYWCH2 | LZE5T | Human | Esophagus | ESCC | 8.42e-08 | 4.17e-01 | 0.0514 |
| 114984 | FLYWCH2 | LZE7T | Human | Esophagus | ESCC | 4.17e-13 | 6.52e-01 | 0.0667 |
| 114984 | FLYWCH2 | LZE8T | Human | Esophagus | ESCC | 2.64e-13 | 4.79e-01 | 0.067 |
| 114984 | FLYWCH2 | LZE20T | Human | Esophagus | ESCC | 3.87e-18 | 3.39e-01 | 0.0662 |
| 114984 | FLYWCH2 | LZE22D1 | Human | Esophagus | HGIN | 1.19e-13 | 4.06e-01 | 0.0595 |
| 114984 | FLYWCH2 | LZE22T | Human | Esophagus | ESCC | 1.87e-07 | 4.17e-01 | 0.068 |
| 114984 | FLYWCH2 | LZE24T | Human | Esophagus | ESCC | 1.00e-24 | 5.66e-01 | 0.0596 |
| 114984 | FLYWCH2 | LZE21T | Human | Esophagus | ESCC | 4.38e-11 | 3.72e-01 | 0.0655 |
| 114984 | FLYWCH2 | LZE6T | Human | Esophagus | ESCC | 3.56e-04 | 2.28e-01 | 0.0845 |
| 114984 | FLYWCH2 | P1T-E | Human | Esophagus | ESCC | 5.49e-22 | 8.24e-01 | 0.0875 |
| 114984 | FLYWCH2 | P2T-E | Human | Esophagus | ESCC | 2.33e-64 | 1.18e+00 | 0.1177 |
| 114984 | FLYWCH2 | P4T-E | Human | Esophagus | ESCC | 5.79e-57 | 1.29e+00 | 0.1323 |
| 114984 | FLYWCH2 | P5T-E | Human | Esophagus | ESCC | 3.33e-39 | 5.24e-01 | 0.1327 |
| 114984 | FLYWCH2 | P8T-E | Human | Esophagus | ESCC | 5.02e-40 | 7.17e-01 | 0.0889 |
| 114984 | FLYWCH2 | P9T-E | Human | Esophagus | ESCC | 2.33e-13 | 2.98e-01 | 0.1131 |
| 114984 | FLYWCH2 | P10T-E | Human | Esophagus | ESCC | 1.04e-28 | 4.05e-01 | 0.116 |
| 114984 | FLYWCH2 | P11T-E | Human | Esophagus | ESCC | 2.48e-28 | 1.07e+00 | 0.1426 |
| 114984 | FLYWCH2 | P12T-E | Human | Esophagus | ESCC | 4.99e-61 | 1.07e+00 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLYWCH2 | insertion | In_Frame_Ins | novel | c.119_120insGTTGGGGCCTCCCGTAACTCTTTA | p.Ser40_Lys41insLeuGlyProProValThrLeuTyr | p.S40_K41insLGPPVTLY | Q96CP2 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| FLYWCH2 | SNV | Missense_Mutation | rs566687400 | c.356N>T | p.Ala119Val | p.A119V | Q96CP2 | protein_coding | tolerated_low_confidence(0.46) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FLYWCH2 | SNV | Missense_Mutation | novel | c.163G>A | p.Ala55Thr | p.A55T | Q96CP2 | protein_coding | tolerated(0.15) | benign(0.325) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FLYWCH2 | SNV | Missense_Mutation | rs376595971 | c.404N>T | p.Ala135Val | p.A135V | Q96CP2 | protein_coding | tolerated_low_confidence(0.44) | benign(0.003) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FLYWCH2 | SNV | Missense_Mutation | c.127G>A | p.Val43Ile | p.V43I | Q96CP2 | protein_coding | deleterious(0.02) | possibly_damaging(0.893) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FLYWCH2 | SNV | Missense_Mutation | rs770341502 | c.175N>T | p.Arg59Cys | p.R59C | Q96CP2 | protein_coding | tolerated(0.11) | probably_damaging(0.988) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FLYWCH2 | SNV | Missense_Mutation | novel | c.383A>G | p.Asn128Ser | p.N128S | Q96CP2 | protein_coding | tolerated_low_confidence(0.68) | benign(0.006) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| FLYWCH2 | SNV | Missense_Mutation | c.31N>A | p.Gly11Ser | p.G11S | Q96CP2 | protein_coding | tolerated(0.09) | benign(0.14) | TCGA-DD-A4NJ-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| FLYWCH2 | SNV | Missense_Mutation | c.31N>T | p.Gly11Cys | p.G11C | Q96CP2 | protein_coding | deleterious(0) | possibly_damaging(0.821) | TCGA-64-1676-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FLYWCH2 | SNV | Missense_Mutation | c.32N>T | p.Gly11Val | p.G11V | Q96CP2 | protein_coding | deleterious(0) | benign(0.258) | TCGA-64-1676-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |